Neurodevelopment at Age 2 Not Worse After ART Conception

Share this content:
Neurodevelopment at Age 2 Not Worse After ART Conception
Neurodevelopment at Age 2 Not Worse After ART Conception

WEDNESDAY, Jan. 18, 2017 (HealthDay News) -- Cognitive, motor, and language development at age 2 years is similar for children born after assisted reproductive technologies (ART) conception and natural conception, according to a study published in the February issue of Obstetrics & Gynecology.

Jacques Balayla, M.D., from the University of Montreal, and colleagues conducted a prospective cohort study to compare cognitive, motor, and language development at 2 years of age in children born after natural conception versus those born after ART. They recruited 2,366 pregnant women, of whom 278 conceived with ART (ovarian stimulation, intrauterine sperm insemination, in vitro fertilization, intracytoplasmic sperm injection, or in vitro maturation). At 24 months postpartum, 175 children in the ART group and 1,345 in the natural conception group underwent neurodevelopmental assessment.

The researchers found that children born after ART showed no difference in the Bayley scales' cognitive scores (B1 = −1.6), composite motor scores (B1 = −1.33), or MacArthur-Bates language scores (B1 = −0.28) after adjustment for relevant confounding variables. There were no significant differences when comparing independent ART techniques or when comparing in vivo or in vitro techniques.

"Children born after ART had similar cognitive, motor, and language development as children born after natural conception at 2 years of age," the authors write. "These findings may be useful in the clinical counseling of patients undergoing ART."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »